Increased Intensity Lymphodepletion Enhances Tumor Treatment Efficacy of Adoptively Transferred Tumor-specific T Cells

Surgery Branch, National Cancer Institute, National Institute of Health, Bethesda, MD 20892, USA.
Journal of immunotherapy (Hagerstown, Md.: 1997) (Impact Factor: 4.01). 11/2009; 33(1):1-7. DOI: 10.1097/CJI.0b013e3181b88ffc
Source: PubMed


Lymphodepletion before adoptive cell transfer (ACT)-based immunotherapies can enhance anti-tumor responses by augmenting innate immunity, by increasing access to homeostatic cytokines, and by depressing the numbers of regulatory T cells and myeloid-derived suppressor cells. Although it is clear that high-dose total body irradiation given together with hematopoietic stem cell (HSC) transplantation effectively enhances ACT, the relationship between the intensity of lymphodepletion and tumor treatment efficacy has not been systematically studied. Using the pmel-1 mouse model of self/tumor-reactive CD8 T cells, we observed a strong correlation between the intensity of the conditioning regimen and the efficacy of ACT-based treatments using linear regression analysis. This was the case for preparative total body irradiation administered either as a single dose (R=0.97, P<0.001) or in fractionated doses (R=0.94, P<0.001). Increased amounts of preparative total body irradiation were directly correlated with progressively more favorable ratios of transferred tumor-reactive CD8 T cells toward endogenous cells with the potential for inhibitory activity including: CD4 cells (potentially T regulatory cells); Gr1 cells (which are capable of functioning as myeloid-derived suppressor cells); and endogenous CD8 and natural killer 1.1 cells (that can act as "sinks" for homeostatic cytokines in the postablative setting). With increasing ablation, we also observed elevated lipopolysaccharide levels in the sera and heightened levels of systemic inflammatory cytokines. Thus, increased intensity lymphodepletion triggers enhanced tumor treatment efficacy and the benefits of high-dose total body irradiation must be titrated against its risks.

Download full-text


Available from: Nicholas P Restifo,
  • Source
    • "First, the combination of oncogene-targeted therapy with specific immunomodulatory therapy may further increase the clinical response and long-term survival of patients [94,110,111]. Pointedly, immune activation may be essential to prevent the emergence of therapy-resistant tumor cells, which can lead to tumor recurrence [112,113]. Hence, the identification of the best agents to prompt oncogene withdrawal will require examination of the efficacy of these therapies with consideration of their ability to induce both cell autonomous and host-dependent mechanisms of tumor regression. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The targeted inactivation of a single oncogene can induce dramatic tumor regression, suggesting that cancers are "oncogene addicted." Tumor regression following oncogene inactivation has been thought to be a consequence of restoration of normal physiological programs that induce proliferative arrest, apoptosis, differentiation, and cellular senescence. However, recent observations illustrate that oncogene addiction is highly dependent upon the host immune cells. In particular, CD4(+) helper T cells were shown to be essential to the mechanism by which MYC or BCR-ABL inactivation elicits "oncogene withdrawal." Hence, immune mediators contribute in multiple ways to the pathogenesis, prevention, and treatment of cancer, including mechanisms of tumor initiation, progression, and surveillance, but also oncogene inactivation-mediated tumor regression. Data from both the bench and the bedside illustrates that the inactivation of a driver oncogene can induce activation of the immune system that appears to be essential for sustained tumor regression.
    07/2014; 2(1):24. DOI:10.1186/2051-1426-2-24
  • Source
    • "The adoptive cell transfer (ACT) combined with lymphodepletion has led to clinical tumor suppression in 50–70% of patients with metastatic melanoma (1). However, the large number of activated and expanded T cells required in the laboratory (more than 1×1010) makes ACT a costly and labor-intensive treatment (2–4). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Oncolytic adenoviruses are modified based on adenovirus serotype 5 (Ad5), which belongs to subgroup C and depends on Coxsackie-adenovirus receptor (CAR) to recognize target cells. However, expression of CAR is generally low or lost in certain tumors including hepatocellular carcinoma (HCC). By contrast, CD46 is highly expressed in various types of malignant tumor cells. Therefore, we constructed an adenovirus vector expressing the human RANTES/CCL5 gene regulated by oxygen-dependent degradation domain (ODD) and analyzed its antitumor effects in vitro and in vivo. The human RANTES/CCL5 gene was fused with ODD by PCR and the recombinant oncolytic adenovirus containing RANTES-ODD, SG511-CCL5-ODD, was constructed by the Gateway system, which infected cells by binding CD46. Viral replication experiments were performed to evaluate the selective replication ability of SG511-CCL5-ODD. RANTES expression was determined by ELISA. The chemotactic test was used to analyze the ability of the expressed RANTES to recruit NK92 cells. The antitumor effects of SG511-CCL5-ODD were examined in HCC xenografts in nude mice. A chimeric oncolytic adenovirus, SG511-CCL5-ODD, was constructed successfully. Cells infected with the recombinant virus were able to express RANTES selectively in different environments controlled by ODD and the expressed RANTES was able to recruit NK92 cells by its chemotactic effect in vitro and improve the anticancer immune response in HCC xenografts in nude mice. The chimeric adenovirus SG511-CCL5-ODD highly expressed the RANTES-ODD fusion gene in the hypoxia of HCC under the control of the ODD and effectively attracted NK92 cells and a high number of immunocytes. These factors had complementary advantages and, in combination, exerted enhanced antitumor efficacy.
    Oncology Reports 12/2012; 29(3). DOI:10.3892/or.2012.2217 · 2.30 Impact Factor
  • Source
    • "Pmel-1 CD8 splenocytes express a transgenic TCR that recognizes gp10025-33 in the context of H-2Db; adoptive transfer of activated Pmel-1 can mediate partial or complete regression of established B16 melanoma in various animal tumor models [23,24]. The B16 melanoma used in these experiments produced about 1 μg TGFβ/106 tumor cells/24 hr. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Tumor antigen-reactive T cells must enter into an immunosuppressive tumor microenvironment, continue to produce cytokine and deliver apoptotic death signals to affect tumor regression. Many tumors produce transforming growth factor beta (TGFbeta), which inhibits T cell activation, proliferation and cytotoxicity. In a murine model of adoptive cell therapy, we demonstrate that transgenic Pmel-1 CD8 T cells, rendered insensitive to TGFbeta by transduction with a TGFbeta dominant negative receptor II (DN), were more effective in mediating regression of established B16 melanoma. Smaller numbers of DN Pmel-1 T cells effectively mediated tumor regression and retained the ability to produce interferon-gamma in the tumor microenvironment. These results support efforts to incorporate this DN receptor in clinical trials of adoptive cell therapy for cancer.
    Journal of Translational Medicine 06/2012; 10(1):127. DOI:10.1186/1479-5876-10-127 · 3.93 Impact Factor
Show more